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Abstract 
Alpha-pyrrolidinovalerophenone (α-PVP) is a designer drug, the mechanism of action of which 
resembles that of cocaine and amphetamine. New data about the side effects of α-PVP are 
emerging. We present a case report of an acute ischemic stroke following the recreational use 
of α-PVP. The ischemic lesions were located in the middle cerebral artery and deep watershed 
areas of the left cerebral hemisphere. Occupational therapy and physiotherapy were initiated, 
and the patient was discharged with only a mild right hemiparesis. 
 © 2021 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Alpha-pyrrolidinovalerophenone (α-PVP), or “flakka” by its street name, is a synthetic 
stimulant used recreationally. α-PVP is related to other cathinone derivates often commonly 
referred to as “bath salts,” and the mechanism of action resembles that of cocaine and amphet-
amine by inhibiting dopamine and norepinephrine reuptake [1]. Unlike older drugs, the ad-
verse effects of newer designer drugs are not as well known. The previously reported serious 
adverse effects of α-PVP included psychosis and catatonia [2], myocardial infarction [3], and 
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Stevens-Johnson syndrome [4], but not stroke. α-PVP is banned in multiple EU countries in-
cluding Finland. Here we present a case report of an acute ischemic stroke following injection 
of α-PVP. 
Case Report 
A Finnish male patient in his sixties with hepatitis C and osteoarthrosis of both knees was 
admitted to the emergency department because of acute right-sided hemiparesis that had 
started a day before the admission. Prior to the onset of hemiparesis, the patient’s friend had 
injected a dose of α-PVP into the patient’s neck. The intended injection site was the left exter-
nal jugular vein, since the peripheral veins were damaged due to numerous injections. Before 
the injection, the drug had been mixed with tap water and injected using a clean needle and a 
microfilter provided by a nonprofit organization aimed at diminishing health complications 
from drug use. 
The clinical neurological evaluation at the emergency department showed right-sided 
hemiparesis, no visual deficits, and no aphasia or dysarthria. A head CT demonstrated infarc-
tions along the left sulcus centralis. Only a small puncture wound without surrounding hema-
toma was found on the patient’s neck. 
CT angiography of the head and neck arteries showed no dissection or other signs of 
trauma of the carotid or vertebral arteries, and no critical stenosis. Only minor atherosclerotic 
plaques were found. In the distal part of the basilar artery, either vasospasm or stenosis due 
to atherosclerosis was suspected. Thrombosis of the left jugular vein was also suspected. 
Aspirin 250 mg p.o. and enoxaparin 40 mg s.c. as a prophylactic dose against deep vein 
thrombosis were administered, and the patient was admitted to the neurology ward. Further 
investigations included a neck ultrasound, which ruled out thrombosis of the jugular vein. 
Head MRI showed multiple new ischemic lesions in the left cerebral hemisphere (Fig. 1). The 
lesions were mainly located in the deep watershed area of the centrum semiovale. MRA of  
the carotid and cerebral arteries did not show vasospasm or clinically relevant atheroscle-
rotic stenosis. There was no indication of puncture of the left internal carotid artery in these 
studies. 
Atrial fibrillation was not found on 48-h ECG monitoring. Transthoracic and transesoph-
ageal echocardiography showed no evidence of endocarditis or intracardial thrombi. Clini-
cally irrelevant, small patent foramen ovale was found. A urine drug screen was positive for 
benzodiazepines, and the patient reported occasional use of benzodiazepines. A full thrombo-
philia workup was negative and along with a normal complete blood count ruled out most 
common thrombophilias and hematological disorders. LDL cholesterol was 2.2 mmol/L, and 
HbA1c was normal. 
The patient was evaluated, and rehabilitation was initiated by an occupational therapist. 
However, the patient left the hospital on the fifth day of his own will before a complete physi-
otherapy evaluation. At discharge, the patient had a mild right-sided hemiparesis but could 
walk with the aid of forearm crutches he had already been using because of osteoarthrosis. 
Prescriptions of aspirin 100 mg and atorvastatin 10 mg once per day were given, and the pa-
tient was advised to continue occupational therapy at the local healthcare center to rehabili-
tate right arm functions. 
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We strongly suspect that the patient’s stroke was caused by the use of α-PVP, although 
the exact mechanism remains unknown. The patient used a clean needle with a microfilter, 
which lowers the risk of embolic adulterants to be the direct cause of the ischemic stroke. The 
comprehensive evaluation ruled out other major causes of stroke, and the onset of the stroke 
was immediately after the α-PVP injection. The urine drug screen was only positive for ben-
zodiazepines, which rules out other confounding substances. 
We did not find previous reports of ischemic strokes caused by α-PVP, although cardio-
vascular events such as myocardial infarction had been previously reported [3]. Structurally 
and pharmacologically synthetic cathinones are similar to amphetamine, and physiological 
changes include hypertension, arrythmia, and vasoconstriction, which are known to cause 
strokes [5]. 
The normal urine drug screen used at the emergency departments in Finland does not 
demonstrate the use of synthetic drugs. As this case demonstrates, patients seeking medical 
aid sometimes willingly share information about illicit drug use, if only they are asked. 
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Fig. 1. Top row: representative 3-mm DWI trace image slices showing scattered restricted diffusion areas 
in the middle cerebral artery and deep watershed areas. Bottom row: FLAIR image slices (1 mm slice thick-
ness) at corresponding levels. The lesions on DWI have a high signal intensity on the FLAIR images, con-
sistent with acute infarction. Further, there are confluent, deep white matter hyperintensities with no dif-
fusion restriction and a distribution consistent with chronic vascular lesions. 
 
